Genetics and Clinical Aspects of Hematologic Neoplasms and Hematopoietic Transplantation

Axis 1: Haematology-oncology in adults

L1: Transplantation of haematopoietic progenitor cells.

1.1. Transplantation of nonconventional haematopoietic progenitor cells (haploidentical, dual).

1.2. Transplantation of haematopoietic progenitor cells in patients with AIDS.

1.3. Cell therapy (mesenchymal, NK cells, etc.)

1.4. Follow-up of transplantation of haematopoietic progenitors (genetics and flow cytometry).

1.5. Biomarkers for prediction of post-transplant complications (genetic polymorphism, proteins, etc.).

1.6. Gene/cell therapy with CAR-T cells

L2: Myeloid neoplasms: Acute myeloid leukaemia and myelodysplastic syndrome.

2.1. Treatment with next-generation drugs.

2.2. Genomics of the tumour cell.

2.3. In vitro drug resistance studies.

2.4. Cytotoxicity studies with NK.

L3: High-grade lymphomas.

3.1. Liquid biopsy (free DNA in plasma) in high-grade lymphomas.

L4: Chronic myeloid leukaemia.

4.1. Studies on discontinuation of tyrosine kinase inhibitors in chronic myeloid leukaemia.

L5: Genetics of haematological neoplasms.

5.1. Genetic markers for diagnosis, prognosis and targeted treatment.

5.2. Genomics of haematological neoplasms: next-generation sequencing.

5.3. Leukaemogenesis models.

5.4 Germ genomic alterations

L6: Clinical research (clinical trials).

6.1. Molecular targets in the treatment of haemato-oncology patients.

6.2. Monoclonal antibodies in the treatment of haematology-oncology patients.

6.3. Cell therapy (mesenchymal, NK cells, etc.

6.4. Gene/cell therapy with CAR-T cells

L7: Electronic management of clinical information.

Axis 2: Paediatric haematology-oncology

L1: Haemoglobinopathies. (CSUR for Hereditary Erythropathology)

1.1 Transplantation of haematopoietic progenitors in haemoglobinopathies

1.2 Clinical monitoring of sickle cell disease from neonatal screening

1.3 Erythrocytapheresis in the Paediatric Sickle Cell Patient

L2: Adjuvant therapy in paediatric haematology-oncology.

L3: Fanconi anaemia.

L3.1 Multidisciplinary follow-up in Fanconi's Anaemia

L4: Solid tumours in children.

L5: Leukaemia in children.